[Form 4] Oric Pharmaceuticals, Inc. Insider Trading Activity
Oric Pharmaceuticals CFO Dominic Piscitelli executed significant stock sales on June 23-24, 2025, through a pre-planned Rule 10b5-1 trading plan established on December 30, 2024. The transactions included:
- June 23: Sale of 584 shares at $10.00 and 450 shares at $10.01
- June 24: Sale of 32,466 shares at weighted average price of $10.5045 (range $10.34-$10.80)
Following these transactions, Piscitelli's direct ownership decreased from 101,233 to 68,317 shares, representing a roughly 32.5% reduction in his holdings. The sales were executed according to a predetermined trading plan, which helps avoid concerns about insider trading by establishing sale parameters in advance. The transactions demonstrate significant insider selling activity by a key executive officer.
Il CFO di Oric Pharmaceuticals, Dominic Piscitelli, ha effettuato vendite significative di azioni il 23 e 24 giugno 2025, seguendo un piano di trading predefinito secondo la Regola 10b5-1, istituito il 30 dicembre 2024. Le operazioni comprendevano:
- 23 giugno: vendita di 584 azioni a 10,00$ e 450 azioni a 10,01$
- 24 giugno: vendita di 32.466 azioni al prezzo medio ponderato di 10,5045$ (intervallo 10,34$-10,80$)
Dopo queste transazioni, la proprietà diretta di Piscitelli è diminuita da 101.233 a 68.317 azioni, rappresentando una riduzione di circa il 32,5% del suo patrimonio azionario. Le vendite sono state eseguite secondo un piano di trading predeterminato, che aiuta a evitare sospetti di insider trading stabilendo in anticipo i parametri di vendita. Queste operazioni evidenziano una significativa attività di vendita da parte di un dirigente chiave.
El CFO de Oric Pharmaceuticals, Dominic Piscitelli, realizó ventas significativas de acciones los días 23 y 24 de junio de 2025, mediante un plan de negociación preestablecido bajo la Regla 10b5-1, establecido el 30 de diciembre de 2024. Las transacciones incluyeron:
- 23 de junio: venta de 584 acciones a 10,00$ y 450 acciones a 10,01$
- 24 de junio: venta de 32.466 acciones a un precio promedio ponderado de 10,5045$ (rango 10,34$-10,80$)
Tras estas operaciones, la propiedad directa de Piscitelli disminuyó de 101.233 a 68.317 acciones, lo que representa una reducción aproximada del 32,5% en sus participaciones. Las ventas se ejecutaron conforme a un plan de negociación predeterminado, que ayuda a evitar preocupaciones sobre el uso de información privilegiada al establecer los parámetros de venta con anticipación. Estas transacciones demuestran una actividad significativa de venta interna por parte de un ejecutivo clave.
Oric Pharmaceuticals의 CFO 도미닉 피시텔리(Dominic Piscitelli)는 2025년 6월 23일부터 24일까지 2024년 12월 30일에 설정된 사전 계획된 Rule 10b5-1 거래 계획을 통해 상당한 주식 매도를 실행했습니다. 거래 내역은 다음과 같습니다:
- 6월 23일: 584주를 주당 10.00달러, 450주를 주당 10.01달러에 매도
- 6월 24일: 가중평균 가격 10.5045달러(범위 10.34~10.80달러)로 32,466주 매도
이 거래 이후 피시텔리의 직접 보유 주식은 101,233주에서 68,317주로 약 32.5% 감소했습니다. 이 매도는 사전에 정해진 거래 계획에 따라 이루어져 내부자 거래 우려를 방지하며, 중요한 임원에 의한 상당한 내부자 매도 활동을 보여줍니다.
Le directeur financier d'Oric Pharmaceuticals, Dominic Piscitelli, a réalisé d'importantes ventes d'actions les 23 et 24 juin 2025, dans le cadre d'un plan de trading préétabli selon la règle 10b5-1, mis en place le 30 décembre 2024. Les transactions comprenaient :
- 23 juin : vente de 584 actions à 10,00$ et 450 actions à 10,01$
- 24 juin : vente de 32 466 actions au prix moyen pondéré de 10,5045$ (plage de 10,34$ à 10,80$)
À la suite de ces transactions, la détention directe de Piscitelli est passée de 101 233 à 68 317 actions, soit une réduction d'environ 32,5 % de ses avoirs. Les ventes ont été réalisées conformément à un plan de trading prédéfini, ce qui permet d'éviter les soupçons d'initiés en établissant à l'avance les paramètres de vente. Ces opérations illustrent une activité de vente interne significative de la part d'un cadre clé.
Der CFO von Oric Pharmaceuticals, Dominic Piscitelli, führte am 23. und 24. Juni 2025 bedeutende Aktienverkäufe durch, basierend auf einem vorab geplanten Rule 10b5-1 Handelsplan, der am 30. Dezember 2024 eingerichtet wurde. Die Transaktionen umfassten:
- 23. Juni: Verkauf von 584 Aktien zu je 10,00$ und 450 Aktien zu je 10,01$
- 24. Juni: Verkauf von 32.466 Aktien zum gewichteten Durchschnittspreis von 10,5045$ (Spanne 10,34$-10,80$)
Nach diesen Transaktionen verringerte sich Piscitellis Direktbesitz von 101.233 auf 68.317 Aktien, was einer Reduktion von etwa 32,5 % seines Bestands entspricht. Die Verkäufe erfolgten gemäß einem vorab festgelegten Handelsplan, der dazu dient, Bedenken hinsichtlich Insiderhandel zu vermeiden, indem Verkaufsparameter im Voraus definiert werden. Die Transaktionen zeigen eine bedeutende Insider-Verkaufsaktivität eines wichtigen Führungskräfte.
- The CFO's stock sales were executed according to a pre-planned Rule 10b5-1 trading plan established on December 30, 2024, indicating compliance with insider trading regulations
- CFO Dominic Piscitelli sold a significant portion (33,500 shares) of his holdings at prices ranging from $10.00 to $10.80, reducing his position by approximately 33% from 101,233 to 68,317 shares
- The substantial reduction in the CFO's equity stake could be interpreted as reduced confidence in the company's near-term prospects
Insights
This Form 4 reveals a significant reduction in holdings by CFO Dominic Piscitelli, who sold a total of 33,500 shares (approximately 33% of his position) over two days. The sales were conducted under a 10b5-1 plan established in December 2024, which typically provides some insulation from negative interpretations as these plans must be set up when the insider doesn't possess material non-public information.
However, the magnitude of the selling warrants attention - particularly the larger block of 32,466 shares on June 24th. While planned sales don't necessarily indicate negative outlook, the substantial percentage reduction in holdings (from 101,233 to 68,317 shares) could suggest the CFO is diversifying personal holdings or potentially sees limited near-term upside at current price levels.
Importantly, this transaction occurred at prices around $10-$10.80 per share. Investors should monitor whether other executives follow with similar selling patterns, which would strengthen the signal. For context, I'd want to examine ORIC's recent stock performance and whether this selling comes after any significant price appreciation or ahead of any scheduled clinical or regulatory catalysts.
The CFO's decision to sell approximately 33% of his direct holdings merits consideration within the broader context of ORIC Pharmaceuticals' clinical development timeline. As a clinical-stage oncology company, ORIC's valuation is heavily dependent on pipeline progress rather than current revenue streams.
The sales occurring at the $10-$10.80 range may reflect the CFO's assessment of the company's near-term prospects relative to its current valuation. For biotech companies, executive selling ahead of important data readouts can sometimes signal caution, though the pre-established 10b5-1 plan mitigates this interpretation somewhat.
Given the competitive landscape in precision oncology, where ORIC operates, investors should cross-reference this selling activity with upcoming clinical milestones for the company's lead assets. If major clinical results are expected in Q3-Q4 2025, this selling pattern takes on greater significance. The biotech sector has been particularly volatile in 2024-2025, and executive behavior often provides subtle indicators of confidence in upcoming catalysts that can drive significant valuation changes in clinical-stage companies.
From a portfolio management perspective, this Form 4 filing represents a moderate bearish signal that should be factored into position sizing decisions for ORIC holdings. The CFO's liquidation of one-third of his position, while planned through a 10b5-1 arrangement, still represents a meaningful reduction in skin-in-the-game for a key financial decision maker.
At approximately $10.50 per share, investors should evaluate whether this price point represents fair value given the company's cash position, burn rate, and clinical pipeline potential. The biotech sector often trades on catalyst expectations, and significant insider selling can sometimes precede periods of limited news flow or anticipated disappointments.
I would recommend comparing this selling pattern with historical insider transactions at ORIC and peer companies of similar market capitalization and clinical stage. If this represents an acceleration of selling or diverges from past patterns, it deserves greater weight in investment decisions. For existing shareholders, this might not warrant immediate liquidation but could justify tightening stop-loss levels or reducing position sizes until additional clarity emerges regarding the company's near-term prospects.
From a governance perspective, this Form 4 reveals important information about executive confidence and alignment with shareholders. While the CFO retains a substantial position (68,317 shares), the 33% reduction in holdings modifies the alignment of interests between this key executive and outside investors.
The implementation of a 10b5-1 trading plan indicates proper governance protocols are being followed, which is positive. However, the timing and volume of sales warrant monitoring by the board's compensation committee to ensure executive incentives remain appropriately aligned with company performance and shareholder returns.
For investors evaluating ORIC's governance profile, it's worth examining whether other executives or board members have established similar trading plans or executed comparable sales. Multiple insiders reducing positions simultaneously would represent a stronger governance signal than an isolated transaction. Additionally, investors should examine recent proxy statements to determine whether the company has implemented or modified any holding requirements for executives, which could provide context for these sales. The board's responsibility is to ensure executives maintain sufficient equity stakes to drive long-term value creation.
Il CFO di Oric Pharmaceuticals, Dominic Piscitelli, ha effettuato vendite significative di azioni il 23 e 24 giugno 2025, seguendo un piano di trading predefinito secondo la Regola 10b5-1, istituito il 30 dicembre 2024. Le operazioni comprendevano:
- 23 giugno: vendita di 584 azioni a 10,00$ e 450 azioni a 10,01$
- 24 giugno: vendita di 32.466 azioni al prezzo medio ponderato di 10,5045$ (intervallo 10,34$-10,80$)
Dopo queste transazioni, la proprietà diretta di Piscitelli è diminuita da 101.233 a 68.317 azioni, rappresentando una riduzione di circa il 32,5% del suo patrimonio azionario. Le vendite sono state eseguite secondo un piano di trading predeterminato, che aiuta a evitare sospetti di insider trading stabilendo in anticipo i parametri di vendita. Queste operazioni evidenziano una significativa attività di vendita da parte di un dirigente chiave.
El CFO de Oric Pharmaceuticals, Dominic Piscitelli, realizó ventas significativas de acciones los días 23 y 24 de junio de 2025, mediante un plan de negociación preestablecido bajo la Regla 10b5-1, establecido el 30 de diciembre de 2024. Las transacciones incluyeron:
- 23 de junio: venta de 584 acciones a 10,00$ y 450 acciones a 10,01$
- 24 de junio: venta de 32.466 acciones a un precio promedio ponderado de 10,5045$ (rango 10,34$-10,80$)
Tras estas operaciones, la propiedad directa de Piscitelli disminuyó de 101.233 a 68.317 acciones, lo que representa una reducción aproximada del 32,5% en sus participaciones. Las ventas se ejecutaron conforme a un plan de negociación predeterminado, que ayuda a evitar preocupaciones sobre el uso de información privilegiada al establecer los parámetros de venta con anticipación. Estas transacciones demuestran una actividad significativa de venta interna por parte de un ejecutivo clave.
Oric Pharmaceuticals의 CFO 도미닉 피시텔리(Dominic Piscitelli)는 2025년 6월 23일부터 24일까지 2024년 12월 30일에 설정된 사전 계획된 Rule 10b5-1 거래 계획을 통해 상당한 주식 매도를 실행했습니다. 거래 내역은 다음과 같습니다:
- 6월 23일: 584주를 주당 10.00달러, 450주를 주당 10.01달러에 매도
- 6월 24일: 가중평균 가격 10.5045달러(범위 10.34~10.80달러)로 32,466주 매도
이 거래 이후 피시텔리의 직접 보유 주식은 101,233주에서 68,317주로 약 32.5% 감소했습니다. 이 매도는 사전에 정해진 거래 계획에 따라 이루어져 내부자 거래 우려를 방지하며, 중요한 임원에 의한 상당한 내부자 매도 활동을 보여줍니다.
Le directeur financier d'Oric Pharmaceuticals, Dominic Piscitelli, a réalisé d'importantes ventes d'actions les 23 et 24 juin 2025, dans le cadre d'un plan de trading préétabli selon la règle 10b5-1, mis en place le 30 décembre 2024. Les transactions comprenaient :
- 23 juin : vente de 584 actions à 10,00$ et 450 actions à 10,01$
- 24 juin : vente de 32 466 actions au prix moyen pondéré de 10,5045$ (plage de 10,34$ à 10,80$)
À la suite de ces transactions, la détention directe de Piscitelli est passée de 101 233 à 68 317 actions, soit une réduction d'environ 32,5 % de ses avoirs. Les ventes ont été réalisées conformément à un plan de trading prédéfini, ce qui permet d'éviter les soupçons d'initiés en établissant à l'avance les paramètres de vente. Ces opérations illustrent une activité de vente interne significative de la part d'un cadre clé.
Der CFO von Oric Pharmaceuticals, Dominic Piscitelli, führte am 23. und 24. Juni 2025 bedeutende Aktienverkäufe durch, basierend auf einem vorab geplanten Rule 10b5-1 Handelsplan, der am 30. Dezember 2024 eingerichtet wurde. Die Transaktionen umfassten:
- 23. Juni: Verkauf von 584 Aktien zu je 10,00$ und 450 Aktien zu je 10,01$
- 24. Juni: Verkauf von 32.466 Aktien zum gewichteten Durchschnittspreis von 10,5045$ (Spanne 10,34$-10,80$)
Nach diesen Transaktionen verringerte sich Piscitellis Direktbesitz von 101.233 auf 68.317 Aktien, was einer Reduktion von etwa 32,5 % seines Bestands entspricht. Die Verkäufe erfolgten gemäß einem vorab festgelegten Handelsplan, der dazu dient, Bedenken hinsichtlich Insiderhandel zu vermeiden, indem Verkaufsparameter im Voraus definiert werden. Die Transaktionen zeigen eine bedeutende Insider-Verkaufsaktivität eines wichtigen Führungskräfte.
FAQ
How many ORIC Pharmaceuticals (ORIC) shares did CFO Dominic Piscitelli sell on June 23-24, 2025?
What was the price range of ORIC shares sold by CFO Piscitelli on June 24, 2025?
How many ORIC shares does CFO Piscitelli own after the June 2025 transactions?
Was ORIC CFO Piscitelli's stock sale part of a pre-planned trading arrangement?
